Jonah Comstock is the Editor in Chief at pharmaphorum. He specializes in health tech journalism, focusing on themes such as healthcare technology, medicine, and alternative medicine, with particular interests in oncology, digital health, and psychedelic research. Jonah's insights and expertise are featured prominently in pharmaphorum.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
The European Commission has granted marketing authorisation to Gilead for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for
A year after officially launching its AI agency offering , EVERSANA is expanding the platform's capabilities and announcing a major pharma
The US FDA announced two De Novo marketing authorisations for novel medical devices this week: A continuous glucose monitor that also monitors
Revolution Medicines' Rasonque (daraxonrasib), the RAS inhibitor that received a standing ovation at ASCO for its doubling of overall survival in
Employers in the United States are facing rising healthcare costs for next year, and drug prices are a major driver of that increase, according to a new survey released today by the Business Group on Health.
Sword Health, a digital therapeutics company that started in the physical therapy space, has acquired digital mental health company Headspace in a deal valued between $200 and $300 million.
The FDA issued approvals for Pfizer and Moderna's 2026 COVID-19 vaccines on Thursday, but is recommending them for the same reduced patient population
The US FDA issued similar warning letters to five different online peptide vendors on 24th August, giving the companies 15 days to respond to accusations of selling unapproved new drugs.
Merck KGaA's recently approved neurofibromatosis type 1 (NF1) therapy Ezmekly has been cleared for routine NHS use in England, becoming an option for children as young as two with the rare disease.
Editor's Note: pharmaphorum is an editorially independent publication owned by EVERSANA.
